UNSPSC 51284038: Oxytetracycline dihydrate

This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O9.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X20I9EN955, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo- but more generally known as oxytetracycline, which bears US NIH Compound Identifier 5280972. European Medicines Agency schedules Oxytetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09579MIG.

UNSPSC 51284038 Oxytetracycline dihydrate is a Commodity code that nominally covers a specific tetracycline antibiotic active pharmaceutical ingredient, but recent state and local solicitations tagged with this code show little alignment with that narrow scope. The code appears in state and local procurement systems with minimal recent activity directly targeting oxytetracycline dihydrate as a standalone pharmaceutical product. Instead, the opportunities recorded under this code span broader pharmaceutical and medical supply procurement — including naloxone kits, drug deactivation systems, first aid supplies for emergency responders, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. This mismatch suggests either inconsistent code assignment by issuing bodies or that the code functions as a catch-all for certain pharmaceutical categories in state and local taxonomy systems rather than as a precise commodity classifier.

The recent opportunities reflect activity across state health departments, county health agencies, and municipal fire departments. Issuing bodies include Seminole County, Florida (pursuing naloxone and drug deactivation systems through an IFB due July 26, 2023), the City of Tampa Fire Department (seeking medical and first aid supplies through an IFB due March 13, 2026, with an estimated contract value of $700,000.00 and an SLBE set-aside), the Texas Health and Human Services Commission (issuing an RFI on direct-to-manufacturer prescription programs due April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (posting an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with distribution through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson). Geographic concentration centers on Florida, Minnesota, and Texas. Given the code's weak alignment with its nominal scope and the sparse activity directly matching oxytetracycline dihydrate procurement, this code shows little relevant recent opportunity for vendors focused on the specific product line its name implies.